- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ind-Swift Laboratories has completed the conversion of 11 lakh Fully Convertible Warrants into 11 lakh new equity shares. These shares, issued at ₹121 each, were subscribed by Essix Biosciences Limited, a part of the Promoter & Promoter Group. This strategic conversion, involving a balance payment of ₹9.98 crore, significantly increases the promoter group's stake. Consequently, the company's paid-up equity share capital now stands at ₹73.48 crore, divided into 7.34 crore equity shares. This move strengthens the capital structure and reflects continued commitment from the promoter group.